Karatzas and Partners Law Firm

News

Karatzas & Partners has been ranked, for another year, as “Top Tier Firm 2020” by the IFLR1000 the market-leading financial law publication for lawyers specialising in international finance in financial institutions, corporates and in private practice. As the review states "Karatzas & Partners is one of strongest firms across all transactional work practice areas in Greece and is known for its cross border work”. You can find more information in the following link: https://bit.ly/30LWsou Furthermore, the Firm’s Partners Catherine Karatzas, Managing Partner, Christina Faitakis, Partner, Anna Manda, Partner, Vassiliki Salaka, Partner are ranked as “Highly Regarded” and Alexandros Metallinos, Partner as “Market Leader”, in their practice areas. Please find more information in the following link: https://bit.ly/2qCwdBc

Karatzas & Partners is advising SAZKA Group on its all-cash, unconditional tender offer for the acquisition of OPAP. The offer consideration exceeds € 1.9 billion. The Information Memorandum for the tender offer has been approved by the Hellenic Capital Market Commission and was published on September 30th, 2019. The acceptance period commenced on October 1st, 2019 and is expected to close on October 29th, 2019. The tender offer represents the largest offer in Greece for more than 10 years and the largest cash tender offer in Greek history

Piraeus Bank S.A. has entered into a strategic partnership with Intrum for the management of Non Performing Exposures (“NPE”) and Real Estate Owned Assets (“REOs”) through the establishment of a market-leading independent non-performing assets servicing platform in Greece.

The agreement values the platform at €410mn. Total purchase price for Ιntrum’s acquisition of 80% of the platform has been agreed at €328mn. Piraeus and Intrum aim for Transaction closing on 1 October 2019.

The Legal 500, worldwide guide on recommended Law firms and Individual Lawyers in over 100 countries, released its 2019 guide. We are proud that Karatzas & Partners Law Firm was ranked among the best - ranked (Tier 1) in the following sectors: Banking, finance and capital markets, Commercial, corporate and M&A, Energy, Projects and privatisation, Real estate & construction, Restructuring & insolvency and in the TMT sector.

Our Law Firm was praised for its “first-class reputation for cutting-edge banking and capital markets work”. For our 'continuous excellent advice' thanks to the team's 'long experience in complex M&A transactions of all sizes'. For our 'highly motivated and proactive team' is commended for its 'smart thinking and resourcefulness' and 'out-of-the-box solutions in terms of deal structuring'.

According to The Legal 500, worldwide guide, Karatzas & Partners provides exceptional service' at the cutting edge of real estate law, often on behalf of investment funds, banks, and major investors and developers, and is one of Greece's market leaders for complex restructurings, both for creditors and debtors.

The Legal 500 worldwide guide praises Karatzas & Partners Law Firm for its 'good expertise on the local regulatory framework' and its 'very professional' lawyers.

We acted as Greek legal counsel for MS Pharma, a leading pharmaceuticals and healthcare solutions company in the Middle East based in Amman, Jordan, which also operates in Turkey and Africa, in the acquisition of the Greek-based generics company Genepharm S.A. in the context of MS Pharma’s expansion into Europe and farther afield. Genepharm develops, manufactures and out-licenses high-value generic pharmaceutical products.  The transaction, which was completed on 30.04.2019, required extensive and specialised  legal due diligence in relation to pharmaceutical products and services, as well as complex corporate matters for a Greek company founded on and active since 1967, an in-depth analysis of the commercial relationships and agreements of Genepharm with other pharmaceutical companies and customers in Greece and abroad with regards to the licensing (in and out) and rights of use of generics’ dossiers, distribution of generics and intellectual property matters in the highly regulated pharmaceutical sector, while in parallel our team worked together with the international legal advisors in drafting, negotiating and concluding the share purchase agreement and other transaction documents. The transaction is one of the significant M&A transactions in Greece for Q1 2019 and in the Greek pharmaceuticals sector.

Page 10 of 19